Spreadsheet Data
Audit the saved peer set and the method inputs behind the blended fair value.
Review the saved peer set across price, scale, operating metrics, and raw valuation multiples.
| Peer | Price | Market Cap | Enterprise Value | Revenue |
|---|
| EBITDA |
|---|
| Net Income |
|---|
| P/E |
|---|
| P/S |
|---|
| EV/EBITDA |
|---|
RV RVMD Revolution Medicines, Inc. FY ended Feb 20, 2026 | $207.88 | $44.56B | $43.17B | $11.58M | -$1.12B | -$1.13B | -34.94x | 3847.69x | — |
IN INCY INCYTE CORP FY ended Feb 03, 2026 | $124.37 | $24.85B | $22.95B | $5.14B | $1.76B | $1.29B | 19.40x | 4.83x | 13.04x |
SR SRPT Sarepta Therapeutics, Inc. FY ended Feb 24, 2026 | $20.86 | $2.20B | $2.78B | $2.20B | -$686.34M | -$713.41M | -2.93x | 1.00x | — |
EX EXEL EXELIXIS, INC. FY ended Feb 02, 2026 | $54.45 | $13.49B | $12.83B | $2.32B | $975.59M | $782.57M | 19.59x | 5.82x | 12.88x |
VR VRTX VERTEX PHARMACEUTICALS INC / MA FY ended Feb 06, 2026 | $541.69 | $137.30B | $134.75B | $12.00B | $4.88B | $3.95B | 35.36x | 11.44x | 27.38x |
See which peer averages feed the weighted fair value and which methods are excluded.
| Method | Type | Avg. Multiple | Coverage | Implied Equity Value | Fair Value / Share | Status |
|---|---|---|---|---|---|---|
EV / EBITDA EVActive | Enterprise Multiple | 18.18x | 3/5 | $1.61B | $2.23 | Included in the active peer mix. |
Price / Sales PSActive | Equity Multiple | 774.16x | 5/5 | $6.39B | $8.85 | Included in the active peer mix. |
Price / Earnings PEExcluded | Equity Multiple | 7.30x | 5/5 | -$2.19B | — | Target fundamentals do not produce a usable positive equity value. |
Open the saved peer table used to audit the fair value view.
| Peer | Price | Market Cap | Enterprise Value | Revenue | EBITDA | Net Income | P/E | P/S | EV/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
RV RVMD Revolution Medicines, Inc. FY ended Feb 20, 2026 | $207.88 | $44.56B | $43.17B | $11.58M | -$1.12B | -$1.13B | -34.94x | 3847.69x | — |
IN INCY INCYTE CORP FY ended Feb 03, 2026 | $124.37 | $24.85B | $22.95B | $5.14B | $1.76B | $1.29B | 19.40x | 4.83x | 13.04x |
SR SRPT Sarepta Therapeutics, Inc. FY ended Feb 24, 2026 | $20.86 | $2.20B | $2.78B | $2.20B | -$686.34M | -$713.41M | -2.93x | 1.00x | — |
EX EXEL EXELIXIS, INC. FY ended Feb 02, 2026 | $54.45 | $13.49B | $12.83B | $2.32B | $975.59M | $782.57M | 19.59x | 5.82x | 12.88x |
VR VRTX VERTEX PHARMACEUTICALS INC / MA FY ended Feb 06, 2026 | $541.69 | $137.30B | $134.75B | $12.00B | $4.88B | $3.95B | 35.36x | 11.44x | 27.38x |
Open the peer-average inputs behind the weighted result.
| Method | Type | Avg. Multiple | Coverage | Implied Equity Value | Fair Value / Share | Status |
|---|---|---|---|---|---|---|
EV / EBITDA EVActive | Enterprise Multiple | 18.18x | 3/5 | $1.61B | $2.23 | Included in the active peer mix. |
Price / Sales PSActive | Equity Multiple | 774.16x | 5/5 | $6.39B | $8.85 | Included in the active peer mix. |
Price / Earnings PEExcluded | Equity Multiple | 7.30x | 5/5 | -$2.19B | — | Target fundamentals do not produce a usable positive equity value. |
